Regeneron Pharmaceuticals, Inc. ( REGN) Evercore 8th Annual Healthcare Conference December 2, 2025 1:20 PM EST ...
Kymera Therapeutics receives US FDA Fast Track Designation for KT-621, an oral STAT6 degrader to treat atopic dermatitis: Watertown, Massachusetts Saturday, December 13, 2025, 18: ...
Company to host video conference call and webcast at 8:00 a.m. ET on Monday, December 8, 2025 ...
Fast Track designation supported by positive results from the KT-621 BroADen Phase 1b atopic dermatitis (AD) patient trial KT-621 BROADEN2 Phase ...
Detailed price information for Kymera Therapeutics Inc (KYMR-Q) from The Globe and Mail including charting and trades.
Stories by SWNS on MSN
Baby born so early her eyes were sealed shut defies odds to survive
A baby girl defied all the odds to survive after being born so early her foot was the size of her dad’s fingertip and her eyes were sealed shut. Brave tot Jemima James, now aged one, was born weighing ...
The U.S. FDA assigned a target action date of April 8, 2026PRINCETON, N.J.--(BUSINESS WIRE)--$BMY #FDA--Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The 2026 GOLD report newly highlights disease activity ...
KT-621 achieved deep STAT6 degradation across both the 100 mg and 200 mg dose groups tested, with median reductions of 94% and 98% in skin and blood, respectively, demonstrating strong translation ...
Bristol Myers Squibb (NYSE: BMY) today announced the presentation of more than 95 data disclosures, including 27 oral presentations, across company-sponsored studies and external collaborations at the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback